08:03 AM EDT, 10/09/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Thursday that its laboratory studies show that Telomir-1 significantly reduces the survival of aggressive triple-negative breast cancer cells.

The company said it plans to expand its findings by testing additional cancer types and conducting further animal studies to prepare for an investigational new drug submission.

The company's shares were up more than 24% in recent Thursday premarket activity.